Search This Blog

Monday, January 31, 2022

Altimmune: FDA Clears Pemvidutide (ALT-801) IND for Obesity

 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its Phase 2 clinical trial of pemvidutide for obesity. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Altimmune expects to initiate the Phase 2 trial in obesity in the first quarter of 2022. The Company previously received IND clearance for pemvidutide in NASH and is currently enrolling subjects with nonalcoholic fatty liver disease (NAFLD) in a Phase 1b trial.

https://finance.yahoo.com/news/altimmune-announces-fda-clearance-pemvidutide-120000469.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.